Why are CSL shares falling today?

CSL shareholders may have mixed feelings today.

| More on:
Cropped shot of an attractive young female scientist working on her computer in the laboratory.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The CSL Ltd (ASX: CSL) share price is down 2% in early trading as the ASX healthcare share feels the effects of the ASX stock market sell-off. CSL shares also went ex-dividend today.

On Friday in the US market, there was a sizeable decline in a number of stocks. Nvidia fell 5.5%, Eli Lilly dropped 2.3%, Microsoft declined 0.7%, Tesla fell 1.8% and so on. The S&P/ASX 200 Index (ASX: XJO) is currently down by 1.3%.

Ex-dividend day

One of the factors that may be impacting CSL shares today is that it went ex-dividend.

An ex-dividend date tells the market when new investors buying shares will miss out on the upcoming dividend. There has to be a cut-off point for deciding who will and who won't receive the dividend.

Anyone who buys today is missing out on the interim dividend payment. Investors who bought CSL shares last week are eligible to receive the dividend, assuming they're still shareholders on the record date (tomorrow).

How much is being paid?

CSL is going to pay a dividend of US$1.19 to shareholders, which at the time of the FY24 first-half result translated into approximately A$1.81 per share (an increase of 12%).

At the current exchange rates, the upcoming payment equates to A$1.80 per share.

CSL is expecting to release information about exchange rates for Australian and New Zealand dollar payments on 14 March 2024.

The ASX healthcare share is planning to pay this dividend on 3 April 2024, which is only a few weeks away.

CSL was able to deliver a bigger dividend after growing net profit after tax (NPAT) by 17% to US$1.9 billion in its FY24 first-half result. It also reported underlying earnings per share (EPS) growth of 11% to US$4.18.

Profit expectations

The company is expecting to report underlying NPATA of between US$2.9 billion to US$3 billion, which would be growth of between 13% to 17%.

Management thinks the business is in a strong position to deliver annualised double-digit earnings growth over the medium term.

On Commsec, the estimates imply the CSL share price is currently valued at 30 times FY24's estimated earnings. It could pay an annual dividend of A$4, according to Commsec, which puts the forecast forward dividend yield at 1.4%.

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL, Microsoft, Nvidia, and Tesla. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool Australia has recommended CSL and Nvidia. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Woman flexes muscles after donating blood.
Healthcare Shares

Top broker predicts 14% upside for CSL share price

Brokers are giving CSL shares a thumbs up right now.

Read more »

Three guys in shirts and ties give the thumbs down.
Healthcare Shares

Why is the Mesoblast share price taking a dive on Tuesday?

This high-flying share is under pressure today. But why?

Read more »

Group of Imugene scientists cheering in the lab after the company received another patent for HER-Vaxx
Healthcare Shares

3 ASX healthcare shares outperforming on quarterly updates

These stocks are charging ahead on an otherwise lacklustre trading day.

Read more »

A happy young couple lie on a wooden deck using a skateboard for a pillow.
Healthcare Shares

Why is the ResMed share price surging again and up 14% in two sessions?

A recent update has gone down exceptionally well with investors.

Read more »

A doctor or medical expert in COVID protection adjusts her glasses, indicating growth or strong share price movement in ASX medical, biotech and health companies
Healthcare Shares

Here is the dividend forecast to 2028 for CSL shares

Are investors going to get healthy dividends from this stock?

Read more »

Two happy scientists analysing test results in a lab
Share Market News

Here's how the ASX 200 market sectors stacked up last week

ASX healthcare shares were strongest among the 11 market sectors last week.

Read more »

A smiling businessman in the city looks at his phone and punches the air in celebration of good news.
Healthcare Shares

ResMed share price jumps 10% on strong quarterly update

ResMed has impressed the market with its third-quarter update.

Read more »

Happy healthcare workers in a labs
Healthcare Shares

Up 74% in 6 months, guess which ASX 200 healthcare stock just hit another all-time high

This company has busily deployed cash over the past six months while growing at a phenomenal pace.

Read more »